July 28th 2025
Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.
July 16th 2025
Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.
July 14th 2025
Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.
July 11th 2025
Those who took olanzapine reported higher levels of satisfaction than patients on placebo.
July 7th 2025
KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.
Patient Education Is Key to Improve Patient Adherence to Cancer Treatment
Jessie Desir, PhD, RN, AMB-BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast cancer.
Facilitating End-of-Life Care for Patients With Breast Cancer
Oncology nurses and APPs provide support and can help to facilitate conversations with patients and families during end-of-life care.
APP Experience Can Garner Conversations Around Restaging of Cancer
Restaging cancer can be an unfamiliar space, but with more experience, APPs can rely less on MDs for guidance in such cases.
Approvals in Cancer Care Call for Multidisciplinary Cooperation
Working with multidisciplinary teams and educating patients are key to treating patients with cancer while navigating newly approved treatments.
Interdisciplinary Collaboration ‘Imperative’ to Streamlining Cancer Care
Working with interdisciplinary teams and nurse navigators to coordinate care across specialties is a facet of oncology nursing that may be overlooked, says an expert.
End-of-Life Conversations: ‘When They Open the Door, You Have to Go In’
Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and often difficult conversations.
FDA Approves Denosumab Biosimiliars for Prior Authorized Indications
Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.
Educating Patients on the Intersection of Cancer Subtypes and DEI
Jessie Desir, PhD, RN, AMB-BC, OCN, discussed the need for awareness about cancer subtypes and their prevalence in certain populations.
Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence
Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.
Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes
Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.
Utilizing Resources to Educate Oncology Nurses, APPs on Latest Advances in Breast Cancer
Erica S. Doubleday, MS, FNP-C, BSN, RN, discussed taking advantage of available resources to provide comprehensive care for patients with breast cancer.
T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Oncology Nurses and APPs Are More Than a ‘Bystander’ in Clinical Trials
The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.
KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer
Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.
PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer
Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.
Relationships With Patients Imperative to AE Management in Cancer Care
Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.
Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Common Adverse Events With Trastuzumab Deruxtecan for Breast Cancer
Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.
Inavolisib Combo Improves Survival in Advanced Breast Cancer
Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Recent and Upcoming Advances in Breast Cancer Treatment
Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.
Managing Chemo-Induced Peripheral Neuropathy in Breast Cancer
La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
New Research Investigating Chemo-Induced Neuropathy in Black Breast Cancer Survivors
An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.
Exploring Research Opportunities for Oncology Nurses, APPs
An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.
Opinion: A Case of Self-Experimentation with Oncolytic Virus Therapy Highlights the Need for More Research
Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.
Opinion: Chromosomal Abnormalities in Healthy Breast Tissue May Be Early Indicators of Cancer Risk
Oncology nurses can educate patients on the implications of these findings
Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes
Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.
Neoadjuvant Niraparib/Dostarlimab Combo May Yield pCRs in BRCS+, ER+/HER2- Breast Cancer
Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.
Study Supports Role of ctDNA in Predicting Outcomes in HR+ Early Breast Cancer
Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.
Addition of Perioperative Atezolizumab Does Not Improve EFS in TNBC
Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.
Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL
Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts
Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer
Understanding How On-Target and Off-Target ADC Toxicities Work